Novel arylsulfoanilide-oxindole hybrid as an anticancer agent that inhibits translation initiation.
Natarajan
Amarnath
A
Laboratory for Translational Research, Harvard Medical School, One Kendall Square, Building 600, 3rd Floor, Cambridge, MA 02139, USA.
Guo
Yuhong
Y
Harbinski
Frederick
F
Fan
Yun-Hua
YH
Chen
Han
H
Luus
Lia
L
Diercks
Jana
J
Aktas
Huseyin
H
Chorev
Michael
M
Halperin
Jose A
JA
D000814:Aniline Compounds / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D000818:Animals; D000970:Antineoplastic Agents / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D002118:Calcium / Q000378:metabolism; D045744:Cell Line, Tumor; D004354:Drug Screening Assays, Antitumor; D006801:Humans; D007211:Indoles / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D051379:Mice; D013329:Structure-Activity Relationship; D013449:Sulfonamides / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology
D000814:Aniline Compounds; D000970:Antineoplastic Agents; D007211:Indoles; D013449:Sulfonamides; D002118:Calcium